UroGen submitted an NDA for UGN-103 in recurrent NMIBC, T-DXd improved PFS in first-line HER2-mutant lung cancer, and more.
News|Articles|February 12, 2025
Oncology Experts Preview Top Abstracts From 2025 ASCO GU
Author(s)Kristi Rosa
Fact checked by: Chris Ryan
Experts highlight the top presentations to watch for at the 2025 Genitourinary Cancers Symposium.
Advertisement
Advertisement
Ahead of this year’s Genitourinary Cancers Symposium, OncLive® asked leading oncologists in the space to share what presentations they are most excited to learn more about during the meeting and why.
Related to this article
Patient-reported QOL and symptom outcomes were similar between belzutifan plus lenvatinib and cabozantinib in previously treated RCC.
Adanma Ayanambakkam, MD, MS, discusses findings from the FIT-001 trial of darlifarnib plus cabozantinib in RCC.
Faculty convened at an OncLive Scientific Interchange and Workshop to weigh how new regimens should reshape sequencing in prostate cancer.
Focal therapy for prostate cancer has evolved over 2 decades, with advances in imaging, patient selection, treatment modalities, and clinical trials.
The top 5 OncLive TV videos of the week cover pancreatic cancer, gastric cancer, GIST, renal cell carcinoma, and chronic lymphocytic leukemia.
The FDA approved daraxonrasib for pancreatic cancer, cleared zanidatamab-based regimens for HER2-positive gastric cancer, and more.
The conditional approval of fanregratinib is supported by pivotal phase 2 data showing a 42.5% objective response rate in pretreated FGFR2-altered intrahepatic cholangiocarcinoma.
Advertisement
Advertisement